2. Novo Nordisk at a glance
Introduction to the company
Novo Nordisk is a global healthcare company
with 90 years of innovation and leadership within:
โข diabetes care
โข insulin
โข injection devices
Thanks to dedicated research into proteins,
Novo Nordisk also holds leading positions within:
โข haemostasis management
โข growth hormone therapy
โข hormone replacement therapy
3.
4. Novo Nordisk Worldwide: > 33,000 employees
Production sites
R&D facilities
Clinical development centres
Affiliates
Representative offices
Regional and business area offices
5. Seattle
Beijing
Denmark
Bangalore
Princeton
R&D locations
โข Copenhagen, Denmark
โข Beijing, China
โข Seattle, WA, USA
โข Princeton, NJ, USA
โข Bangalore, India
Clinical Development centres
โข Zรผrich, Switzerland
โข Beijing, China
โข Princeton, NJ, USA
โข Tokyo, Japan
>3800 staff
today, 5000
staff in 2020
Global
R&D
6. The ability to attract talent in Denmark is key to us
81
3898
154
194
27
R&D 4354
Employees in R&D 01-Mar-2013
7. Additional Novo Nordisk R&D facts
โข > DKK 10 billion R&D investment
โข Ranked 4th
out of 20 international pharmaceutical and biotech
companies listed as best employers by Science Magazine
โข 778 scientific publication in 2010-11 (2010 h-index: 26)
โข 25 PhD and 6 post docs supported through the LIFEPHARM PhD
school at University of Copenhagen focussing on pharmacology.
โข ~ 100 PhD/PostDoc science students from Europe, North
America and Asia
โข Top rating in Dow Jones Sustainability Index for the last ten
years
8. 8Industry talent requirements and challenges
We rely on excellent talent within all our competency
areas to sustain growth
E.coli
Yeast
Mammalian cells
Prefilled pens
Durable pens
Oral delivery
Liquid delivery
Sustained release
Subc. delivery
Amino acid substitution
Acylation
Medical insight
Trial design
Execution
Therapy area expertise
Modification
12. STAR PostDoc Fellows 2013
Active and completed 1998 โ 30 June 2013
Burnham Institut
Medical Research
Clinical Medical Regulatory OfficesR&D locations
Berkley
McGill
University
Loyola
Consiglio Nazionale
delle Ricerche
Chapel Hill
University
Princeton
San Francisco
University
Sigma Aldrich
(SAFC)
Stanford
University
Toronto
University
Washington
University
Vrije
University
Harvard
Dublin
University
Geneva
University
Institute for
Biomedicine and
Health Science
Justus-Liebig
University
Karolinska
Institutet
Kings
College
Linkรถping
University
Lund
University
Manchester
University
Martin Luther
University
Nottingham
University
Santiago de
Compostela
University
Uppsala
University
The Hebrew
University-Hadassah
Setsunan University,
Osaka, Japan
Tokyo University
Fudan University
13. Novo Nordisk STAR fellows
Professional Qualifications
โข Strong competences from active research environments
โข International experience and networks
โข Good publications (and PhD thesis) and/or patent applications
โข Skills in new technologies
โข High personal ambitions
16. LIFEPHARM
The Novo NordiskโLIFE In Vivo Pharmacology Centre
Public โ Private โ Partnership
Established 1/9/2010
Aim
โขReinforcement of section of pharmacology and toxicology @ LIFE
โขContinued output of PhD candidates with โin vivoโ expertise
โขEnsure the continuation of the In Vivo PhD Program
Funding
โข9.1 M Euro 2010-2015
โข 6 mill Euros from Novo Nordisk A/S
โข 3.1 mill Euros from LIFE
Resources
โข24 PhD scholarships
โข5 Postdoctoral fellowships (2 years each)
โขProfessorship in clinical pharmacology & toxicology
Framework for an InnoLIFE
PhD programme
18/05/14
17. โข Novo Science Ambassadors
โข Novo Nordisk and Novozymes have established a team of young Novo
Scholarship recipients in order to stimulate the interest for natural and
medical science in the schools.
โข The ambassadorsโ lectures are free and can be booked at www.formidling.dk
Novo Science Ambasadors
17Presentation title Date
18. Recently: Elite Post Doc programme
with Oxford University
โข A recruitment platform for international top
talents within diabetes research
โข An international platform for branding NN as
a top-science employer
โข A platform for on-campus recruitment
activities
โข A platform for expanding scientific
collaboration between NN and UO
โข 3-year fellowships fully funded by Novo
Nordisk
Objectives Scope
18November 2013
19. Recently: Elite Post Doc programme
with Stanford University
โข A recruitment platform for international top
talents within immunology research
โข An international platform for branding NN as
a top-science employer
โข A platform for on-campus recruitment
activities
โข A platform for expanding scientific
collaboration between NN and Stanford
โข 2 to 3-year fellowships fully funded by Novo
Nordisk
Objectives Scope
19November 2013
Institute for Immunity,
Transplantion and Infection
20. Slide no 20 โข โข
Evaluation of Early innovation/research
New metrics for evaluation of the innovation
outcome such as:
โข networks created,
โข access to novel technology & implementation
โข access to important know-how & implementation
on top of the classical metrics such as:
โข publications,
โข patent applications filed,
โข science citations etc.
21. Novo Nordisk R&D career paths
โข To clarify
development
opportunities
โข To specify
qualifiers for
different job
types and
levels
Production sites: Bagsvรฆrd, Denmark - Chartes, France - Clayton, US - Gentofte, Denmark - Hillerรธd, Denmar - Hjรธring, Denmark - Kalundborg, Denmark - Koriyama, Japan - Kรธbe, Denmark - Mexico City, Mexico - Montes Claros, Brazil - Mรฅlรธv, Denmark - Tianjin, China - Tizi ouzou, Algeria - Vรฆrlรธse, Denmark.
R&D facilities: Bagsvรฆrd, Denmark - Beijing, China - Gentofte, Denmark - Hayward, US - Hillerรธd, Denmark - Mรฅlรธv, Denmark - New Brunswick, US
Clinical development centres: Beijing, China - Princeton, US - Tokyo, Japan - Zurich, Switzerland
Regional and business area offices:
Affiliates:
Representative offices:
For an overview of companies in the Novo Nordisk group, see pp. 100-101 (at the NN power point)
Novo Nordisk R&D is global with sites in USA, China and India โ but the vast majority of our R&D efforts, and +4300 R&D staff, are centred at our sites around Copenhagen. Hence talent attraction in the MVA region is important to Denmark.
More that 1000 are employed in the CMR functions in the affiliates.
Key figures on Novo Nordisk R&D
2012 R&D spend: 10,897 MDKK โ 14% of sales
LIFEPHARM included, ~100 active PhD and post docs when in cluding LIFEPHARM
Novo Nordisk key competencies the enrire drug discovery and develop value chain. From deep insight to molecular mechanism of disease and pharmacology, over protein engineering, expression and formulation all the way to clinical trials execution. To contiue to be successfully Novo Nordisk will need to recruit the most talented work force possible.
Why is talent attraction important? We believe that that the ability to attract and manage talents has a direct plosive effect on our long term growth; talents, diversity and the ability to perform are all key ingredients in successful innovation - and thus growth.
Skift โ kun by โ fรฅ ny tal og byer
Knyt en kommentar
2, 3 og 5
3, 4 og 5 gemmes
2-3 similar elite post doc programmes envisioned within the next years.
2-3 similar elite post doc programmes envisioned within the next years.
